23. CYP2B6*6 allele and age substantially reduce steady‐state ketamine clearance in chronic pain patients: impact on adverse effects
Date: Feb 23, 2015
Abstract Aim Ketamine analgesia is limited by low intrinsic efficacy compounded by large interindividual variability in drug responses, possibly due to the heterogeneity in drug concentration. The CYP2B6*6 allele is associated with substantially reduced ketamine metabolism in vitro, and therefore, may affect ketamine clearance. Our aims were to examine the impact of the CYP2B6*6 allele on ketamine plasma clearance, and on adverse...
No comments:
Post a Comment